Together, these results suggest that in HCC patients with high LTβR expression, the expression level of HOIP may serve as a previously unrecognized prognostic marker and that inhibition of LUBAC may be of therapeutic value, especially in such patients. The gene discussed is LTBR; the disease is hepatocellular carcinoma.